A treatment candidate for moderate to severe nonproliferative diabetic retinopathy failed to meet its phase 2b study primary endpoint, according to a press release from Aerpio Pharmaceuticals.
A total of 9.6% of patients who received twice-daily AKB-9778 had an improvement of two or more steps in the study eye diabetic retinopathy severity score compared with 3.8% of patients who received placebo in the TIME-2b study. The difference was not statistically significant.
In all qualified eyes, which included study eyes and fellow eyes that met the inclusion/exclusion criteria, 8.6% improved two or
Uncategorized